JOHANNESBURG (Reuters) - The acting chief executive officer of South Africa's Cipla Medpro said on Monday the generic drug firm has not received any communication from Cipla Ltd that an acquisition deal has been put on hold.
The Economic Times, citing the chairman of Cipla Ltd, reported on Monday that Cipla Ltd's $215 million bid for control of the South African company is on hold.
"I am aware of the that report but I have not been able to verify it and we have not received any communication from Cipla Ltd about its withdrawal from the talks," Johan du Preez, Cipla Medpro's acting CEO, told Reuters.
"As far as we are concerned, the talks are ongoing."
Shares in Cipla Medpro fell 4.2 percent to 9.00 rand, still above the 8.55 rand Cipla Ltd put on the table in November.
(Reporting by Tiisetso Motsoeneng; editing by David Dolan)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app